People · Operator

Amina Odidi

Named in public records as an officer, director or promoter · active 2011–2018 · Pharmaceuticals

1
Companies
4
Filings
$17.5M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Intellipharmaceutics International Inc.PharmaceuticalsSeries A$17.5M$31.4M2011
Operator network

Amina Odidi at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Eldon R. Smith · 3 companies · 1 sharedEldon R. SmithEldon Smith · 2 companies · 1 sharedEldon SmithAndrew Patient · 1 companies · 1 sharedAndrew PatientAndrew R. Patient · 1 companies · 1 sharedAndrew R. PatientBahadur Madhani · 1 companies · 1 sharedBahadur MadhaniBahadur R. Madhani · 1 companies · 1 sharedBahadur R. MadhaniIsa Odidi · 1 companies · 1 sharedIsa OdidiJohn N. Allport · 1 companies · 1 sharedJohn N. AllportKenneth Keirstead · 1 companies · 1 sharedKenneth KeirsteadKenneth R. Keirstead · 1 companies · 1 sharedKenneth R. Keirst…Michael R. Campbell · 1 companies · 1 sharedMichael R. Campbe…Patrick N. Yat · 1 companies · 1 sharedPatrick N. YatShameze N. Rampertab · 1 companies · 1 sharedShameze N. Ramper…Intellipharmaceutics International Inc. · $17.5M raisedIntellipharmaceutics …Amina OdidiAO
Amina Odidi Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Amina Odidi on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Eldon R. Smith13
Eldon Smith12
Bahadur R. Madhani11
Shameze N. Rampertab11
Isa Odidi11
Kenneth R. Keirstead11
Kenneth Keirstead11
Andrew Patient11
Bahadur Madhani11
Michael R. Campbell11
John N. Allport11
Andrew R. Patient11
Patrick N. Yat11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.